BRAF and melanoma: Interestingly, the ERK inhibitor SCH772984, which was developed as a treatment for melanoma resistant to BRAF targeted therapies [41], was effective at reducing proliferation in all four monolayer models and two of the four 3D aggregate models, with low EC50 values.